As of Mar 28, 2026, Bajaj Healthcare Ltd (Pharma - Formulators) has a deep value score of 63/100 (rated Strong). Earnings are accelerating. 1Y return vs Nifty 500: -56%.
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Export-led API business transformation driving margin recovery with CNS drug pipeline providing optionality
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Magnesium L-Threonate launch gaining traction in cognitive health segment
Impact: +₹50 Cr revenue
“Successful launch in Q3 FY26 with initial market response”
CNS drug trial completion expected to unlock regulatory approvals
Impact: +₹200 Cr revenue
“CDSCO approval for Phase III trials received in Q3 FY26”
Higher-margin export business becoming dominant revenue stream
“API exports grew 109.8% YoY, currently at ~45% of total revenue”
Risks that could prevent re-rating or deepen the value trap
Domestic API prices drop 20%+ due to competition
Impact: -300 bps margin impact
Management view: Diversification into exports reducing domestic dependency
Monitor: Domestic API revenue growth rate
Suvorexant trial results delayed beyond Q1 FY27
Impact: -150 bps margin impact
Management view: Multiple pipeline drugs reducing single-point failure risk
Monitor: Number of active clinical trials
Forward-looking targets from management for FY27
Revenue Growth Target
25%
Implied PAT Growth
30%
OPM Guidance
21%
Capex Plan
₹150 Cr
Credit Growth Target
0%
NIM Guidance
0%
Key Milestones
• Cenobamate trial results
• Magtein revenue ramp
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +31% | -7% | Stable |
| PAT (Net Profit) | +33% | -17% | Stable |
| OPM | 19.0% | +100 bps | Stable |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Bajaj Healthcare Ltd has a deep value score of 63/100 (rated Strong). This score is calculated from three components
Bajaj Healthcare Ltd's quarterly profit (PAT) growth trajectory
Bajaj Healthcare Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
Bajaj Healthcare Ltd's earnings momentum is Steady — consistent growth.
Bajaj Healthcare Ltd's valuation metrics
Bajaj Healthcare Ltd's revenue and margin trends
Bajaj Healthcare Ltd's trailing twelve month (TTM) performance
Bajaj Healthcare Ltd key facts
Bajaj Healthcare Ltd shows strong deep value signals — good score (63/100), accelerating earnings, and significant underperformance vs Nifty.
Pharma - Formulators deep value sector overview
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
Bajaj Healthcare Ltd has 3 key growth catalysts identified from recent earnings analysis
Bajaj Healthcare Ltd has 2 key risks worth monitoring
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
